Chemomab names Donald Marvin CFO, EVP & COO; outgoing interim CFO stays as advisor

Chemomab Therapeutics Ltd.

Donald Marvin appointed CFO, EVP, and COO effective November 8, 2021.
Sigal Fattal's engagement as interim CFO concluded; she will serve as senior consultant to Marvin.
Marvin receives $460k base salary, 45% bonus potential, $25k signing bonus, and equity (1.5% + 0.5% performance) vesting over 4 years.
Marvin has over 35 years experience; previous roles include EVP/CFO at Lodo Therapeutics, Chairman/CEO at Concentric, co-founder of Orchid BioSciences.
CEO Dale Pfost cites Marvin's expertise in building life sciences companies through organic growth and strategic M&A.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Donald Marvin

Chief Financial Officer, Executive Vice President and Chief Operating Officer

CMMB · Chemomab Therapeutics Ltd.

Effective: 2021-11-08
Filed: November 8, 2021, 6:59 PM ET

On November 8, 2021, the Company issued a press release announcing that, on November 8, 2021, it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.

Departed (interim)

Sigal Fattal

Interim Chief Financial Officer

CMMB · Chemomab Therapeutics Ltd.

Effective: 2021-11-08
Successor: Donald Marvin
Filed: November 8, 2021, 6:59 PM ET

On November 8, 2021, Chemomab Therapeutics Ltd. (the “Company”) and Ms. Sigal Fattal mutually agreed to conclude Ms. Fattal’s engagement as Interim Chief Financial Officer of the Company and its wholly-owned subsidiary Chemomab Ltd. (the “Subsidiary”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Donald Marvin was appointed as Chief Financial Officer, Executive Vice President and Chief Operating Officer at Chemomab Therapeutics Ltd..

Action: appointed
Role: Chief Financial Officer, Executive Vice President and Chief Operating Officer

Exact text from the filing

On November 8, 2021, the Company issued a press release announcing that, on November 8, 2021, it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Sigal Fattal departed as Interim Chief Financial Officer at Chemomab Therapeutics Ltd..

Action: concluded engagement
Role: Interim Chief Financial Officer

Exact text from the filing

On November 8, 2021, Chemomab Therapeutics Ltd. (the “Company”) and Ms. Sigal Fattal mutually agreed to conclude Ms. Fattal’s engagement as Interim Chief Financial Officer of the Company and its wholly-owned subsidiary Chemomab Ltd. (the “Subsidiary”).

View on SEC.gov

Chemomab Therapeutics Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-21-003411

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.